Bilcare post net consolidated sales at Rs 238.47 cr; a growth of 27% for the quarter ended

Pune, July 30, 2009: Bilcare Ltd., service provider to the pharmaceutical companies spanning across their value chain from drug discovery to market posted its results for the quarter ended June 30th 2009.

The India Standalone Sales for the first quarter ended June 30, 2009 stood at Rs.128.51 crores as against Rs.113.76 crores in the same quarter of the previous year, showing a growth of 13%. This resulted in the higher EBITDA for India Standalone at Rs.37.24 crores from Rs.32.21 crores in the corresponding quarter of the previous year, showing a growth of 16%.

The Overseas business of the Company continued to show robust growth achieving sales of Rs.109.96 crores in the first quarter of the current year from Rs.73.74 crores in corresponding quarter of the previous year, a growth of 49%. The EBITDA from Overseas business grew to Rs.18.53 crores from Rs.13.51 crores in the corresponding quarter of the previous year, a growth of 37%.

The Consolidated Sales for the quarter ended June 30, 2009 thus stood at Rs.238.47 crores, showing a growth of 27% over the corresponding quarter of the previous year; with the Consolidated EBITDA increasing to Rs.55.77 crores from Rs.45.72 crores, a growth of 22%.
About Bilcare :

Headquartered in India, Bilcare is an integrated service provider to the global pharmaceutical sector across their value chain through its key business activities namely: Pharma Packaging Innovation, Global Clinical Services and Non-Clonable Technologies. These business activities encompass research, development, manufacturing and supply of products, processes, and services to the Pharma and Healthcare domain. Technologies business focuses on unique range of applications viz. security & product authentication, Track & Trace e-pedigree, medication compliance & Personalized Healthcare Management System. Bilcare operates state-of-the-art Manufacturing and Research facilities in India, Singapore, USA & UK and has regional offices in Brazil, Germany, China & Australia, while partnering with the global pharmaceutical sector by providing value solutions to address their key concerns i.e. counterfeit, compliance, cost communication and convenience.